Nucala (Mepolizumab)

Mepolizumab is a monoclonal antibody that binds to interleukin‑5, blocking its interaction with the IL‑5 receptor on eosinophil precursors and mature eosinophils. This inhibition reduces eosinophil production, activation, and survival, leading to lower eosinophil levels in blood and tissues and thereby decreasing eosinophil‑driven inflammation.

The dosing regimen for Nucala is determined by the prescribing clinician based on the patient’s specific indication, weight, and clinical response. Healthcare providers set the dose and administration schedule according to approved labeling and individual patient needs.

Safety data for Nucala in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and benefits with their healthcare professional.

To request Nucala, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, cold‑chain shipping details and necessary import documentation.

Nucala belongs to the class of IL‑5 antagonists, which specifically target eosinophilic inflammation. Compared with broader biologics such as anti‑IgE or anti‑IL‑4/13 agents, mepolizumab offers a focused mechanism that may be preferred for patients with high eosinophil counts and frequent exacerbations despite standard therapy.

Nucala must be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. If the product has been outside the recommended temperature range, it should not be used.

Nucala is given as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection is performed by a qualified healthcare professional in a clinical setting, following aseptic technique and the dosing schedule prescribed by the treating physician.

The most serious risks include severe allergic reactions such as anaphylaxis, hypersensitivity reactions, and rare immune‑mediated conditions. Patients should be monitored for signs of rash, swelling, difficulty breathing, or other systemic symptoms, and immediate medical attention should be sought if they occur.

Nucala is contraindicated in patients with known hypersensitivity to mepolizumab or any of the product’s excipients. It should also be avoided in individuals receiving live attenuated vaccines or those with active parasitic infections until the infection is adequately treated.